Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm

Preventive Medicine

Volumn 98, Issue , 2017, Pages 5-14

  Tota, Joseph E ^a,b   Bentley, James ^c   Blake, Jennifer ^d   Coutlée, François ^e   Duggan, Máire A ^f   Ferenczy, Alex ^b   Franco, Eduardo L ^b   Fung Kee Fung, Michael ^g   Gotlieb, Walter ^b   Mayrand, Marie Hélène ^h   McLachlin, Meg ⁱ   Murphy, Joan ^j   Ogilvie, Gina ^k   Ratnam, Sam ^b,l  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d The Society of Obstetricians and Gynaecologists of Canada   (Canada)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY OF OTTAWA   (Canada)

^h UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ UNIVERSITY OF WESTERN ONTARIO   (Canada)

^j UNIVERSITY OF TORONTO   (Canada)

^k UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^l MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

more..

Author keywords

Cervical cancer; HPV testing; Screening

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SCREENING; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; NONHUMAN; PAPANICOLAOU TEST; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; CANADA; DIAGNOSTIC TEST; EARLY CANCER DIAGNOSIS; ISOLATION AND PURIFICATION; PAPILLOMAVIRIDAE; PROCEDURES; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

CANADA; DIAGNOSTIC TESTS, ROUTINE; EARLY DETECTION OF CANCER; FEMALE; HUMANS; PAPILLOMAVIRIDAE; UTERINE CERVICAL NEOPLASMS;

EID: 85014529712     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2016.11.029     Document Type: Article

References (98)

1. Adegoke, O., Kulasingam, S., Virnig, B., Cervical cancer trends in the United States: a 35-year population-based analysis. J. Women's Health 21 (2012), 1031–1037.
2. Arbyn, M., Castle, P.E., Offering self-sampling kits for HPV testing to reach women who do not attend in the regular cervical cancer screening program. Cancer Epidemiol. Biomark. Prev. 24 (2015), 769–772.
3. Arbyn, M., Bergeron, C., Klinkhamer, P., Martin-Hirsch, P., Siebers, A.G., Bulten, J., Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet. Gynecol. 111 (2008), 167–177.
4. Arbyn, M., Raifu, A.O., Weiderpass, E., Bray, F., Anttila, A., Trends of cervical cancer mortality in the member states of the European Union. Eur. J. Cancer 45 (2009), 2640–2648.
5. Arbyn, M., Verdoodt, F., Snijders, P.J., Verhoef, V.M., Suonio, E., Dillner, L., Minozzi, S., Bellisario, C., Banzi, R., et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 15 (2014), 172–183.
6. Belinson, J.L., Hu, S., Niyazi, M., Pretorius, R.G., Wang, H., Wen, C., Smith, J.S., Li, J., Taddeo, F.J., et al. Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal and vaginal self-collected specimens: implications for vaginal self-collection. Int. J. Cancer 127 (2010), 1151–1157.
7. Berkhof, J., Coupe, V.M., Bogaards, J.A., van Kemenade, F.J., Helmerhorst, T.J., Snijders, P.J., Meijer, C.J., The health and economic effects of HPV DNA screening in The Netherlands. Int. J. Cancer 127 (2010), 2147–2158.
8. Blatt, A.J., Kennedy, R., Luff, R.D., Austin, R.M., Rabin, D.S., Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 123 (2015), 282–288.
9. Bray, F., Carstensen, B., Moller, H., Zappa, M., Zakelj, M.P., Lawrence, G., Hakama, M., Weiderpass, E., Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol. Biomark. Prev. 14 (2005), 2191–2199.
10. Brotherton, J.M., Fridman, M., May, C.L., Chappell, G., Saville, A.M., Gertig, D.M., Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 377 (2011), 2085–2092.
11. Bulkmans, N.W., Berkhof, J., Rozendaal, L., van Kemenade, F.J., Boeke, A.J., Bulk, S., Voorhorst, F.J., Verheijen, R.H., van Groningen, K., et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370 (2007), 1764–1772.
12. Burger, E.A., Ortendahl, J.D., Sy, S., Kristiansen, I.S., Kim, J.J., Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br. J. Cancer 106 (2012), 1571–1578.
13. Canadian Task Force on Preventive Health, C, Dickinson, J., Tsakonas, E., Conner Gorber, S., Lewin, G., Shaw, E., Singh, H., Joffres, M., Birtwhistle, R., et al. Recommendations on screening for cervical cancer. CMAJ 185 (2013), 35–45.
14. Carozzi, F.M., Del Mistro, A., Confortini, M., Sani, C., Puliti, D., Trevisan, R., De Marco, L., Tos, A.G., Girlando, S., et al. Reproducibility of HPV DNA testing by hybrid capture 2 in a screening setting. Am. J. Clin. Pathol. 124 (2005), 716–721.
15. Castellsague, X., Diaz, M., de Sanjose, S., Munoz, N., Herrero, R., Franceschi, S., Peeling, R.W., Ashley, R., Smith, J.S., et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J. Natl. Cancer Inst. 98 (2006), 303–315.
16. Castle, P.E., Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol., 123, 2015, 566.
17. Castle, P.E., Lorincz, A.T., Mielzynska-Lohnas, I., Scott, D.R., Glass, A.G., Sherman, M.E., Schussler, J.E., Schiffman, M., Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible. J. Clin. Microbiol. 40 (2002), 1088–1090.
18. Castle, P.E., Sideri, M., Jeronimo, J., Solomon, D., Schiffman, M., Risk assessment to guide the prevention of cervical cancer. J. Low. Genit. Tract Dis. 12 (2008), 1–7.
19. Cuzick, J., Clavel, C., Petry, K.U., Meijer, C.J., Hoyer, H., Ratnam, S., Szarewski, A., Birembaut, P., Kulasingam, S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119 (2006), 1095–1101.
20. de Kok, I.M., van Rosmalen, J., Dillner, J., Arbyn, M., Sasieni, P., Iftner, T., van Ballegooijen, M., Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ, 344, 2012, e670 Clinical research ed.
21. de Sanjose, S., Quint, W.G., Alemany, L., Geraets, D.T., Klaustermeier, J.E., Lloveras, B., Tous, S., Felix, A., Bravo, L.E., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 11 (2010), 1048–1056.
22. Dillner, J., Rebolj, M., Birembaut, P., Petry, K.U., Szarewski, A., Munk, C., de Sanjose, S., Naucler, P., Lloveras, B., et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ, 337, 2008, a1754 Clinical research ed.
23. Dillner, J., Kjaer, S.K., Wheeler, C.M., Sigurdsson, K., Iversen, O.E., Hernandez-Avila, M., Perez, G., Brown, D.R., Koutsky, L.A., et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ, 341, 2010, c3493.
24. Drolet, M., Benard, E., Boily, M.C., Ali, H., Baandrup, L., Bauer, H., Beddows, S., Brisson, J., Brotherton, J.M., et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect. Dis. 15 (2015), 565–580.
25. Elit, L., Saskin, R., Raut, R., Elliott, L., Murphy, J., Marrett, L., Sociodemographic factors associated with cervical cancer screening coverage and follow-up of high grade abnormal results in a population-based cohort. Gynecol. Oncol. 128 (2013), 95–100.
26. El-Zein, M., Richardson, L., Franco, E.L., Cervical cancer screening of HPV vaccinated populations: cytology, molecular testing, both or none. J. Clin. Virol. 76:Suppl. 1 (2016), S62–S68.
27. Flores, Y.N., Bishai, D.M., Lorincz, A., Shah, K.V., Lazcano-Ponce, E., Hernandez, M., Granados-Garcia, V., Perez, R., Salmeron, J., HPV testing for cervical cancer screening appears more cost-effective than Papanicolau cytology in Mexico. Cancer Causes Control 22 (2011), 261–272.
28. Franco, E.L., Cuzick, J., Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 26:Suppl. 1 (2008), A16–A23.
29. Franco, E.L., Cuzick, J., Hildesheim, A., de Sanjose, S., Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24:Suppl. 3 (2006), S171–S177.
30. Franco, E.L., Mahmud, S.M., Tota, J., Ferenczy, A., Coutlee, F., The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch. Med. Res. 40 (2009), 478–485.
31. Gage, J.C., Schiffman, M., Katki, H.A., Castle, P.E., Fetterman, B., Wentzensen, N., Poitras, N.E., Lorey, T., Cheung, L.C., et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J. Natl. Cancer Inst., 2014, 106.
32. Garland, S.M., Hernandez-Avila, M., Wheeler, C.M., Perez, G., Harper, D.M., Leodolter, S., Tang, G.W., Ferris, D.G., Steben, M., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356 (2007), 1928–1943.
33. Harper, D.M., Franco, E.L., Wheeler, C.M., Moscicki, A.B., Romanowski, B., Roteli-Martins, C.M., Jenkins, D., Schuind, A., Costa Clemens, S.A., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006), 1247–1255.
34. Huh, W.K., Williams, E., Huang, J., Bramley, T., Poulios, N., Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening. Appl. Health Econ. Health Policy 13 (2015), 95–107.
35. Isidean, S.D., Mayrand, M.H., Ramanakumar, A.V., Gilbert, L., Reid, S.L., Rodrigues, I., Ferenczy, A., Ratnam, S., Coutlee, F., et al. Human papillomavirus testing versus cytology in primary cervical cancer screening: end-of-study and extended follow-up results from the Canadian cervical cancer screening trial. Int. J. Cancer 139:11 (2016), 2456–2466 (Dec 1).
36. Jastania, R., Geddie, W.R., Chapman, W., Boerner, S., Characteristics of apparently false-negative digene hybrid capture 2 high-risk HPV DNA testing. Am. J. Clin. Pathol. 125 (2006), 223–228.
37. Jemal, A., Ward, E., Thun, M., Declining death rates reflect progress against cancer. PLoS One, 5, 2010, e9584.
38. Joura, E.A., Ault, K.A., Bosch, F.X., Brown, D., Cuzick, J., Ferris, D., Garland, S.M., Giuliano, A.R., Hernandez-Avila, M., et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol. Biomark. Prev. 23 (2014), 1997–2008.
39. Joura, E.A., Giuliano, A.R., Iversen, O.E., Bouchard, C., Mao, C., Mehlsen, J., Moreira, E.D. Jr., Ngan, Y., Petersen, L.K., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N. Engl. J. Med. 372 (2015), 711–723.
40. Katki, H.A., Wacholder, S., Solomon, D., Castle, P.E., Schiffman, M., Risk estimation for the next generation of prevention programmes for cervical cancer. Lancet Oncol. 10 (2009), 1022–1023.
41. Katki, H.A., Kinney, W.K., Fetterman, B., Lorey, T., Poitras, N.E., Cheung, L., Demuth, F., Schiffman, M., Wacholder, S., et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 12 (2011), 663–672.
42. Katki, H.A., Schiffman, M., Castle, P.E., Fetterman, B., Poitras, N.E., Lorey, T., Cheung, L.C., Raine-Bennett, T., Gage, J.C., et al. Benchmarking CIN 3 + risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J. Low. Genit. Tract Dis. 17 (2013), S28–S35.
43. Kerner, J., Liu, J., Wang, K., Fung, S., Landry, C., Lockwood, G., Zitzelsberger, L., Mai, V., Canadian cancer screening disparities: a recent historical perspective. Curr. Oncol. 22 (2015), 156–163.
44. Kinney, W., Wright, T.C., Dinkelspiel, H.E., DeFrancesco, M., Thomas Cox, J., Huh, W., Increased cervical cancer risk associated with screening at longer intervals. Obstet. Gynecol. 125 (2015), 311–315.
45. Kitchener, H.C., Almonte, M., Thomson, C., Wheeler, P., Sargent, A., Stoykova, B., Gilham, C., Baysson, H., Roberts, C., et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 10 (2009), 672–682.
46. Kjaer, S.K., Frederiksen, K., Munk, C., Iftner, T., Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J. Natl. Cancer Inst. 102 (2010), 1478–1488.
47. Lazcano-Ponce, E., Lorincz, A.T., Cruz-Valdez, A., Salmeron, J., Uribe, P., Velasco-Mondragon, E., Nevarez, P.H., Acosta, R.D., Hernandez-Avila, M., Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 378 (2011), 1868–1873.
48. Lazcano-Ponce, E., Lorincz, A.T., Torres, L., Salmeron, J., Cruz, A., Rojas, R., Hernandez, P., Hernandez, M., Specimen self-collection and HPV DNA screening in a pilot study of 100,242 women. Int. J. Cancer 135 (2014), 109–116.
49. Lehtinen, M., Paavonen, J., Wheeler, C.M., Jaisamrarn, U., Garland, S.M., Castellsague, X., Skinner, S.R., Apter, D., Naud, P., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13 (2012), 89–99.
50. Lofters, A.K., Moineddin, R., Hwang, S.W., Glazier, R.H., Low rates of cervical cancer screening among urban immigrants: a population-based study in Ontario, Canada. Med. Care 48 (2010), 611–618.
51. Louvanto, K., Chevarie-Davis, M., Ramanakumar, A.V., Franco, E.L., Ferenczy, A., HPV testing with cytology triage for cervical cancer screening in routine practice. Am. J. Obstet. Gynecol. 210:474 (2014), e1–e7.
52. Markowitz, L.E., Dunne, E.F., Saraiya, M., Chesson, H.W., Curtis, C.R., Gee, J., Bocchini, J.A. Jr., Unger, E.R., Centers for Disease, C, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 63 (2014), 1–30.
53. Mayrand, M.H., Duarte-Franco, E., Rodrigues, I., Walter, S.D., Hanley, J., Ferenczy, A., Ratnam, S., Coutlee, F., Franco, E.L., Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 357 (2007), 1579–1588.
54. Meijer, C.J., Berkhof, J., Castle, P.E., Hesselink, A.T., Franco, E.L., Ronco, G., Arbyn, M., Bosch, F.X., Cuzick, J., et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 124 (2009), 516–520.
55. Mitchell, H., Medley, G., Gordon, I., Giles, G., Cervical cytology reported as negative and risk of adenocarcinoma of the cervix: no strong evidence of benefit. Br. J. Cancer 71 (1995), 894–897.
56. Munoz, N., Bosch, F.X., de Sanjose, S., Herrero, R., Castellsague, X., Shah, K.V., Snijders, P.J., Meijer, C.J., Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348 (2003), 518–527.
57. Munoz, N., Bosch, F.X., Castellsague, X., Diaz, M., de Sanjose, S., Hammouda, D., Shah, K.V., Meijer, C.J., Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 111 (2004), 278–285.
58. Nanda, K., McCrory, D.C., Myers, E.R., Bastian, L.A., Hasselblad, V., Hickey, J.D., Matchar, D.B., Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann. Intern. Med. 132 (2000), 810–819.
59. Naucler, P., Ryd, W., Tornberg, S., Strand, A., Wadell, G., Elfgren, K., Radberg, T., Strander, B., Johansson, B., et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 357 (2007), 1589–1597.
60. Naud, P.S., Roteli-Martins, C.M., De Carvalho, N.S., Teixeira, J.C., de Borba, P.C., Sanchez, N., Zahaf, T., Catteau, G., Geeraerts, B., et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum. Vaccin. Immunother. 10 (2014), 2147–2162.
61. Nygard, M., Saah, A., Munk, C., Tryggvadottir, L., Enerly, E., Hortlund, M., Sigurdardottir, L.G., Vuocolo, S., Kjaer, S.K., et al. Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine. Clin. Vaccine Immunol. 22 (2015), 943–948.
62. Ogilvie, G.S., Krajden, M., van Niekerk, D.J., Martin, R.E., Ehlen, T.G., Ceballos, K., Smith, L.W., Kan, L., Cook, D.A., et al. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial — the HPV FOCAL Study. Br. J. Cancer 107 (2012), 1917–1924.
63. Ogilvie, G.S., Naus, M., Money, D.M., Dobson, S.R., Miller, D., Krajden, M., van Niekerk, D.J., Coldman, A.J., Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: an ecological analysis. Int. J. Cancer 137 (2015), 1931–1937.
64. Ogilvie, G.S., Krajden, M., van Niekerk, D., Smith, L.W., Cook, D., Ceballos, K., Lee, M., Gentile, L., Gondara, L., et al. HPV for Cervical cancer screening (HPV FOCAL): complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid based cytology for cervical cancer. Int. J. Cancer 140:2 (2017), 440–448 (Jan 15).
65. Palmer, T.J., McFadden, M., Pollock, K.G., Kavanagh, K., Cuschieri, K., Cruickshank, M., Cotton, S., Nicoll, S., Robertson, C., HPV immunisation and cervical screening-confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study. Br. J. Cancer 114 (2016), 582–589.
66. Petrosky, E., Bocchini, J.A. Jr., Hariri, S., Chesson, H., Curtis, C.R., Saraiya, M., Unger, E.R., Markowitz, L.E., Centers for Disease, C, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb. Mortal. Wkly Rep. 64 (2015), 300–304.
67. Popadiuk, C., Gauvreau, C.L., Bhavsar, M., Nadeau, C., Asakawa, K., Flanagan, W.M., Wolfson, M.C., Coldman, A.J., Memon, S., et al. Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada. Curr. Oncol. 23 (2016), S56–S63.
68. Racey, C.S., Withrow, D.R., Gesink, D., Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and meta-analysis. Can. J. Public Health 104 (2013), e159–e166.
69. Richardson, L., Tota, J., Franco, E., Optimizing technology for cervical cancer screening. Expert Rev. Obstet. Gynecol. 6 (2011), 343–353.
70. Ronco, G., Cuzick, J., Pierotti, P., Cariaggi, M.P., Dalla Palma, P., Naldoni, C., Ghiringhello, B., Giorgi-Rossi, P., Minucci, D., et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ, 335, 2007, 28 Clinical research ed.
71. Ronco, G., Giorgi-Rossi, P., Carozzi, F., Confortini, M., Dalla Palma, P., Del Mistro, A., Ghiringhello, B., Girlando, S., Gillio-Tos, A., et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 11 (2010), 249–257.
72. Ronco, G., Dillner, J., Elfstrom, K.M., Tunesi, S., Snijders, P.J., Arbyn, M., Kitchener, H., Segnan, N., Gilham, C., et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383 (2014), 524–532.
73. Roteli-Martins, C.M., Naud, P., De Borba, P., Teixeira, J.C., De Carvalho, N.S., Zahaf, T., Sanchez, N., Geeraerts, B., Descamps, D., Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum. Vaccin. Immunother. 8 (2012), 390–397.
74. Sankaranarayanan, R., Nene, B.M., Shastri, S.S., Jayant, K., Muwonge, R., Budukh, A.M., Hingmire, S., Malvi, S.G., Thorat, R., et al. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360 (2009), 1385–1394.
75. Sasieni, P., Castanon, A., Cuzick, J., Screening and adenocarcinoma of the cervix. Int. J. Cancer 125 (2009), 525–529.
76. Saslow, D., Runowicz, C.D., Solomon, D., Moscicki, A.B., Smith, R.A., Eyre, H.J., Cohen, C., American Cancer, S, American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J. Clin. 52 (2002), 342–362.
77. Saslow, D., Solomon, D., Lawson, H.W., Killackey, M., Kulasingam, S.L., Cain, J., Garcia, F.A., Moriarty, A.T., Waxman, A.G., et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J. Clin. 62 (2012), 147–172.
78. Schiffman, M., Castle, P.E., Jeronimo, J., Rodriguez, A.C., Wacholder, S., Human papillomavirus and cervical cancer. Lancet 370 (2007), 890–907.
79. Schiffman, M., Wentzensen, N., Wacholder, S., Kinney, W., Gage, J.C., Castle, P.E., Human papillomavirus testing in the prevention of cervical cancer. J. Natl. Cancer Inst. 103 (2011), 368–383.
80. Serrano, B., Alemany, L., Tous, S., Bruni, L., Clifford, G.M., Weiss, T., Bosch, F.X., de Sanjose, S., Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect. Agents Cancer, 7, 2012, 38.
81. Sherman, M.E., Wang, S.S., Wheeler, C.M., Rich, L., Gravitt, P.E., Tarone, R., Schiffman, M., Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol. Biomark. Prev. 12 (2003), 1038–1044.
82. Siebers, A.G., Klinkhamer, P.J., Grefte, J.M., Massuger, L.F., Vedder, J.E., Beijers-Broos, A., Bulten, J., Arbyn, M., Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA 302 (2009), 1757–1764.
83. Smith, L.W., Khurshed, F., van Niekerk, D.J., Krajden, M., Greene, S.B., Hobbs, S., Coldman, A.J., Franco, E.L., Ogilvie, G.S., Women's intentions to self-collect samples for human papillomavirus testing in an organized cervical cancer screening program. BMC Public Health, 14, 2014, 1060.
84. Spayne, M., Rabeneck, L., Guerriero, L., Successes and challenges in population-based cancer screening. Healthc. Q., 2015, 16–22 17 Spec No.
85. Spence, A.R., Goggin, P., Franco, E.L., Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev. Med. 45 (2007), 93–106.
86. Tota, J., Mahmud, S.M., Ferenczy, A., Coutlee, F., Franco, E.L., Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era. Sex. Health 7 (2010), 376–382.
87. Tota, J.E., Ramanakumar, A.V., Jiang, M., Dillner, J., Walter, S.D., Kaufman, J.S., Coutlee, F., Villa, L.L., Franco, E.L., Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am. J. Epidemiol. 178 (2013), 625–634.
88. Tota, J.E., Ramana-Kumar, A.V., El-Khatib, Z., Franco, E.L., The road ahead for cervical cancer prevention and control. Curr. Oncol. 21 (2014), e255–e264.
89. Tota, J.E., Bentley, J., Blake, J., Coutlee, F., Duggan, M.A., Ferenczy, A., Franco, E.L., Fung-Kee-Fung, M., Gotlieb, W., et al. Approaches for triaging women who test positive for human papillomavirus in cervical cancer screening. Prev. Med. 98 (2017), 15–20.
90. Verhoef, V.M., Bosgraaf, R.P., van Kemenade, F.J., Rozendaal, L., Heideman, D.A., Hesselink, A.T., Bekkers, R.L., Steenbergen, R.D., Massuger, L.F., et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol. 15 (2014), 315–322.
91. von Karsa, L., Arbyn, M., De Vuyst, H., Dillner, J., Dillner, L., Franceschi, S., Patnick, J., Ronco, G., Segnan, N., et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 1 (2015), 22–31.
92. Walboomers, J.M., Jacobs, M.V., Manos, M.M., Bosch, F.X., Kummer, J.A., Shah, K.V., Snijders, P.J., Peto, J., Meijer, C.J., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189 (1999), 12–19.
93. World Health Organization, Human papillomavirus vaccines: WHO position paper, October 2014-recommendations. Vaccine 33 (2015), 4383–4384.
94. Wright, T.C. Jr., Stoler, M.H., Behrens, C.M., Apple, R., Derion, T., Wright, T.L., The ATHENA human papillomavirus study: design, methods, and baseline results. Am. J. Obstet. Gynecol., 206, 2012 46 e1-46 e11.
95. Wright, T.C., Stoler, M.H., Behrens, C.M., Sharma, A., Zhang, G., Wright, T.L., Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol. Oncol. 136 (2015), 189–197.
96. Wright, T., Huang, J., Baker, E., Garfield, S., Hertz, D., Cox, J.T., The budget impact of cervical cancer screening using HPV primary screening. Am. J. Manag. Care 22 (2016), e95–e105.
97. Young, T.K., Kliewer, E., Blanchard, J., Mayer, T., Monitoring disease burden and preventive behavior with data linkage: cervical cancer among aboriginal people in Manitoba, Canada. Am. J. Public Health 90 (2000), 1466–1468.
98. Zhou, H., Mody, R.R., Luna, E., Armylagos, D., Xu, J., Schwartz, M.R., Mody, D.R., Ge, Y., Clinical performance of the Food and Drug Administration-approved high-risk HPV test for the detection of high-grade cervicovaginal lesions. Cancer Cytopathol. 124 (2016), 317–323.